Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atorvastatin plus bempedoic acid versus higher-dose atorvastatin in prediabetic hypercholesterolemia
IRCT20250131064580N1Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences (Research Affairs)
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in hypercholesterolemia and prediabetes comparing Atorvastatin 40 mg with Atorvastatin 20 mg plus bempedoic acid 180 mg (2 arms). Primary endpoints: Low-density lipoprotein cholesterol, High-density lipoprotein cholesterol and 13 more. Started Apr 2025; status: completed.
02
Drugs
atorvastatinbempedoic acid
03
Conditions
hypercholesterolemiaprediabetes
Beyond the preview
Go deeper on IRCT20250131064580N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250131064580N1.